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ABSTRACT 
 
 
Background: Treatment delays have been linked to decreased survival in women with 
breast cancer. Many women rely on their spouse or partner to provide support following 
breast cancer diagnosis. To date, little research has explored the effects of partner 
supportive behaviors on timely receipt of recommended cancer treatment and ultimately 
cancer survival.   
Objective: To determine whether women identified as having lower partner support 
experience delays in time to first breast cancer treatment relative to women with highly 
supportive partners.  
Methods: Women aged 18-79 who were diagnosed with incident and primary breast 
cancer within the past 12 months and included in the Kentucky Cancer Registry were 
recruited for the cohort study between November 2009 and December 2013. The new 
measure of Partner Supportive Behaviors in Cancer Care (5 item short form) was used to 
determine women’s recall of partner supportive behaviors during and after cancer 
treatment and recovery. Unadjusted and adjusted linear regression, Kaplan-Meier, and 
Cox-Proportional Hazard modeling were used to determine the relationship between 
partner support and time to first treatment for women with breast cancer.  
Results: Lower partner support was not significantly associated with longer time to first 
treatment for women with breast cancer, relative to women with highly supportive 
partners. Time to first treatment among 94 women with lower partner support was 22.2 
days (SE: 1.9), compared to 21.7 days (SE: 1.5) for 144 women with moderate partner 
support, and 21.4 days (SE: 0.8) for women with highly supportive partners. The adjusted 
hazard ratio for those with lower partner support was 0.95 (95% CI: 0.76-1.18). This 
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pattern held for analyses of time to first cancer treatment independent of treatment type, 
by specific treatment (surgery and chemotherapy), and for analyses within early and late 
cancer stage.  
Conclusions: To our knowledge, no other studies have examined the association between 
partner support and time to first cancer treatment. Future studies may consider the effect 
of other negative partner behaviors such as intimate partner violence or behaviors 
interfering with cancer care that may directly impact timely receipt of cancer treatment.  
 
Keywords: breast cancer, treatment, partner support, delays 
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INTRODUCTION 
 
Breast cancer remains the most common cancer diagnosis for women, despite the fact 
that incidence rates have stabilized from 2002 to 2011.
1
 Breast cancer treatment options 
include surgery, chemotherapy, hormonal therapy, and radiation, with the majority of 
women receiving surgery as their first treatment.
2
 While both screening and treatment 
options have played a role in the reduction of breast cancer mortality thus far, delays in 
treatment can negatively impact rate of survival.
3-5
  
A meta-analysis of 38 studies showed a significant difference of survival between 
those with treatment delays less than 3 months and those with treatment delays of 3 to 6 
months for women with breast cancer.
6
 In a study focusing specifically on breast cancer 
in adolescents and young adults, a surgical delay of greater than 6 weeks influenced 
survival compared to those who received surgery closer to their diagnosis.
7
 Because 
delays in receipt of first treatment have been shown to impact survival, this study focuses 
on delays in treatment among women with breast cancer; time to first treatment will be 
the primary outcome.  
Many women look to their partner for the provision of social, emotional, and 
financial support following breast cancer diagnosis. Figueiredo et al found that 70% of 
women consider their partner as a confidant, and about 50% of these women identified 
their partner as their most important confidant.
8
 The perception of partner unsupportive 
behaviors, such as changing the topic or being critical of coping strategies, can impact the 
well-being and distress of women with breast cancer, mostly due to the suppression of 
communication.
9
 Similarly, the presence or the perception of interpersonal factors that 
hinder communication, known as social constraints, between patient and partner can lead 
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to decreased levels of both individual and relationship well-being, and lead to negative 
daily outcomes in the lives of breast cancer patients.
10
  
While the previously mentioned studies have determined that unsupportive partner 
behaviors can prevent women from openly communicating or expressing concerns 
following breast cancer diagnosis, limited research exists looking for the effect of these 
behaviors on timely receipt of cancer care. In the present report, we will examine the 
relationship between unsupportive partner behaviors and time to first treatment for 
women with breast cancer. We hypothesize that a delay in therapy will be seen for 
women identified as having little to no support system, compared to women with a high 
level of partner support. 
 
METHODS 
 
Participant Recruitment 
 
 Women aged 18 to 79 diagnosed with an incident and primary case of breast 
cancer within the past 12 months were recruited from the Kentucky Cancer Registry 
(KCR) between November 2009 and December 2013.  Researchers first reached out to 
physicians before contacting potential participants. Eligible women were then contacted 
by mail and given information on how to provide consent or decline participation. KCR 
made an additional attempt by phone to contact women who had not responded. Once 
consent was obtained, trained research staff at the University of Kentucky Survey 
Research Center (SRC) performed phone interviews to collect participant survey 
responses and demographic information. These interviews averaged 30 minutes.  
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Demographics 
 Demographic variables can be found in Table 1 for our total study population and 
for each level of partner support (low, moderate, or high). Demographic variables include 
age at diagnosis (mean ± standard error), the number of comorbidities (mean ± standard 
error), monthly income, classified as high or low, level of education, private insurance 
versus other insurance, stage at diagnosis, classified as stage 1/stage 2 (early stage) or 
stage 3/stage 4 (late stage), race, classified as Non-Hispanic White versus other, and 
smoking status, classified as current, former, never.  
 
Measures  
 We defined our exposure, partner support, by creating 3 groups: low support, 
moderate support, or high support. Women were placed in 1 of the 3 groups based on 
their responses to 5 survey questions representing a new measure, Partner Supportive 
Behaviors in Cancer Care (PSB-C).
11
 The questions were as follows: has your current 
partner or the person you were with when diagnosed gone to doctors’ visits or 
appointments with you? Spent time with you when you were in the hospital? Been 
involved with your medical care, like asking your doctor questions or trying to learn 
more about your illness? Done something unexpected that would make you happy? 
Willingly made small sacrifices when you needed it or skipped a social activity to be with 
you?  A Cronbach’s alpha of 0.71 was calculated to measure the internal consistency of 
the 5 questions.  
 Dichotomous variables for each question were created based on survey responses 
and women received a 1 if their partners exhibited the behavior identified in the question 
 8 
a little, some, or a lot, or a 0 if their partners did not exhibit the behavior identified in the 
question at all. The sum of these dichotomous variables allowed us to create the three 
groups of partner support. A PSB-C score of 1 to 3 points (out of a possible 5) placed 
women in the low support group, PSB-C score of 4 placed women in the moderate 
support group, and a PSB-C score of 5 placed the women in the high support group. For 
the purpose of our study, highly supportive partners serve as the reference group.  
 Our outcome, time to first treatment, was treated as a continuous variable, and is 
measured in days between diagnosis and receipt of first treatment. The data includes time 
to first treatment information for any type of treatment received, and also provides 
specific treatment information, such as time to first treatment based on specific treatment 
type. Everyone in the present study received treatment following breast cancer diagnosis.  
 
Statistical Analysis  
Comparisons were made across the 3 levels of partner support for all demographic 
variables. F-values were used to assess the differences between groups for continuous 
variables (age at diagnosis and number of comorbidities), and chi-square values were 
used for categorical variables (income, education, private insurance, stage at diagnosis, 
race, and smoking status,). Unadjusted and adjusted linear regression was performed to 
represent the effects of partner support on time to first treatment. The first adjustment, 
age and stage, was made based on a minimum sufficient set identified with a Directed 
Acyclic Graph (DAG) (Figure 1). The second adjustment, including age, stage, income, 
and comorbidities, was made based on the minimum sufficient DAG set and the 
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statistically significant relationships between income and comorbidities and partner 
support, as shown in Table 1.  
 Kaplan-Meier and Cox Proportional Hazard modeling were used to identify 
differences in time to first treatment based on level of partner support.  Kaplan-Meier 
survival plots were created to determine the relationship between different levels of 
partner support and time to first treatment for all treatment types, within stage, and within 
types of treatment (surgery and chemotherapy). Unadjusted and adjusted hazard ratios 
were identified examining the relationship between partner support and time to first 
treatment for the following groups: time to first treatment for all treatment types, time to 
first treatment for those with early or late stage breast cancer, time to first treatment for 
those receiving surgery first, and time to first treatment for those receiving chemotherapy 
first. All statistical analysis was performed with SAS version 9.3.  
 
RESULTS 
A total of 4,628 eligible women were identified in Kentucky and 1,245 (26.9%) 
completed the telephone survey. Items measuring partner supportive behaviors were only 
asked of women in a relationship at cancer diagnosis; 886 were identified as being in a 
relationship (marriage or partnership). Our final study cohort included 844 women, after 
excluding women with missing values for stage, partner support, comorbidities, income, 
and time to first treatment (Figure 2). Among 844 women, 94 (11.1%) women were 
classified as having lower partner support (PSB-C of 1-3 of a maximum score of 5), 144 
(17.1%) as having moderate partner support (PSB-C score=4), and 606 (71.8%) as having 
highly supportive partners (PSB-C score=5).  
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Table 1 provided data to determine demographic and cancer-related correlates of 
the three levels of partner supportive behaviors. Women with lower partner support were 
found to have more physical health comorbidities (p=0.01), lower monthly family income 
(p=0.005), and not to have private health insurance coverage (p=0.03) when compared to 
women with more supportive partners. Lower partner support was not associated with 
age, education, race, cancer stage at diagnosis, or smoking status. Based on this 
evaluation of correlates with partner support, only income, the number of comorbid 
conditions, and insurance coverage were significantly associated with partner support as 
our primary exposure.   
Table 2, Figure 3, and Table 3 provide the results of the association between 
partner supportive behaviors and time to first cancer treatment using linear regression, 
Kaplan Meier curves, and Cox Proportional Hazards modeling, respectively. From Table 
2, women identified as having lower partner support had a slightly higher time to first 
cancer treatment, at 22.2 days (SE: 1.9), while women with moderate partner support had 
a time to first cancer treatment of 21.7 days (SE: 1.5) and women with highly supportive 
partners had a time to first cancer treatment of 21.4 days (SE: 0.8). Differences in days to 
first cancer treatment by PSB-C groupings were not statistically significant for 
unadjusted or adjusted models.  
Figure 3 represents Kaplan-Meier curves for the three PSB-C groups and time to 
first cancer treatment. Similar to the results of linear regression, no significant differences 
were observed for the association between partner support and time to first cancer 
treatment (p=0.93). Cox Proportional hazard ratios estimating the probability of 
experiencing delays in time to first cancer treatment potentially associated with lower 
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partner support are presented in Table 3. Again, lower partner support was not 
significantly associated with a longer time to first cancer treatment in unadjusted or 
adjusted hazard ratio models (adjusted HR: 0.95; 95% CI: 0.76, 1.18).  
Kaplan Meier curves and Cox-Proportional Hazard modeling were repeated to 
examine the relationship between partner support and time to first treatment within early 
and late cancer stage at diagnosis (Figure 4, Table 4, Figure 5, and Table 5). Among the 
233 women diagnosed at a later breast cancer stage, there was a suggestion that lower 
partner support may actually be associated with shorter time to first treatment, though not 
statistically significant (adjusted HR: 1.15, 95% CI: 0.73, 1.82) (Figure 5 and Table 5).  
In Figure 6, Kaplan-Meier curves were provided for the three levels of PSB-C and 
time to first cancer treatment for women receiving surgery as their first treatment. Again, 
lower PSB-C scores were not significantly associated with longer time to first treatment 
(p=0.83). Table 6 provides the unadjusted and adjusted hazard ratios for partner support 
and time to treatment for women whose first treatment was surgery. Although 
representing a possible delay in time to first treatment for women with low partner 
support, there is no statistically significant association (adjusted HR: 0.91, 95% CI: 0.72, 
1.14).  
Finally, these same analyses were repeated for time to first cancer treatment for 
women who received chemotherapy as their first form of treatment. Similar to those 
diagnosed with later stage breast cancer, women with lower support receiving 
chemotherapy as their first form of treatment actually experienced a shorter time to first 
treatment, though not statistically significant (adjusted HR: 2.65; 95% CI: 0.74, 
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9.43)(Table 7). Limited power makes this analysis less reliable, as most women in our 
study received surgery as their first form of cancer treatment.   
 
DISCUSSION 
 Lower PSB-C scores indicating fewer partner supportive behaviors were not 
significantly associated with longer time to first cancer treatment. Although a delay was 
observed based on unadjusted and adjusted linear regression and hazard ratios for most 
analyses, we cannot conclude that partner support is associated with longer time to first 
treatment for women with breast cancer. These findings were consistently not significant 
when adjusting for potential confounders, within cancer stage, and within specific cancer 
treatments (surgery and chemotherapy).  
Our inability to find an association between partner support and time to first 
cancer treatment may be explained by a lack of power due to the majority of women 
having highly supportive partners (71.8%). Our exposure, partner support, may have been 
misclassified, as women may have struggled to acknowledge unsupportive partner 
behaviors, causing an inaccurate representation of the measure. Additionally, measuring 
partner support based solely on responses to 5 survey questions may not truly reflect the 
extent of unsupportive partner behaviors.  
Manne et al concluded that there are associations between negative responses 
from a spouse and psychological outcomes for patients with cancer, regardless of the 
presence of positive spouse responses.
12
 In our present study, it could be that partner 
behaviors not measured by our PSB-C variable elicit these negative responses between 
patient and spouse, even if the spouse is identified as supportive based on our scale.  
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Interestingly, a higher prevalence of violence has been identified among women 
diagnosed with cancer compared to other populations.
13
 With our measure, PSB-C, we 
may have misclassified the more impactful partner behavior influences on time to first 
cancer treatment. Further investigation is needed to determine if the presence of other 
partner behaviors, such as intimate partner violence, play a role in the measurement of 
partner support and its overall impact on women’s ability to obtain cancer care in a 
timely manner.  
A strength of this study was the use of the Kentucky Cancer Registry to recruit 
eligible participants. The KCR includes all women diagnosed with biopsy confirmed 
cancer each year from 1995-the present. All 120 counties are included in KCR, thus 
representing a full census or population base of all cancer cases. It is possible that those 
agreeing to participate in this survey may have been of higher income or education. 
However, another study utilizing this dataset addressed this potential bias, with 
participation rates being higher for those living in Appalachian counties (29.9%) 
compared to those living in non-Appalachian counties (25.9%) (p=0.01). In this way, 
Appalachian residence serves as a proxy for lower income and less education since those 
variables were based on self-reporting and not provided through KCR. This finding 
supports the generalizability of our study sample to that of those included in KCR.     
Our study analyzed the effect of partner unsupportive behaviors on time to first 
treatment for women with breast cancer; however, we know the majority of women 
received surgery as their first treatment (93%). Other studies have shown decreased 
survival for delays in receipt of chemotherapy following surgery for women with breast 
cancer.
14, 15
 Future research may consider the impact of partner support on timely receipt 
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of adjuvant chemotherapy following surgery for women with breast cancer. Partner 
unsupportive behaviors may play a larger role in the recovery phase following surgery 
and leading up to first chemotherapy.  
In conclusion, we observed that lower partner support was not significantly 
associated with longer time to first cancer treatment. Health care providers should 
consider directing their attention to other partner behaviors that may directly impact 
receipt of timely cancer care, such as intimate partner violence. Future studies should 
focus on improving the classification of partner unsupportive behaviors and seeing if this 
change in classification influences time to first treatment.  
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Figure 1. Directed Acyclic Graph displaying potential confounding factors in determining 
the relationship between partner support and time to first treatment. Variables in red are 
considered the minimum sufficient set for adjusting for the relationship between exposure 
and outcome.  
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Figure 2. A flow chart representing study cohort participant selection. 
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Table 1. Demographics for study cohort and for the 3 groups of partner support, including 
unadjusted analysis analyzing differences between the groups for each demographic 
variable.  
 
 Total 
 
(N=844) 
 
Low Support 
 
(N=94) 
Moderate 
Support 
 
(N=144) 
High 
Support 
 
(N=606) 
DF X
2
 or F-
value 
p-value 
Age at diagnosis  (KCR)  
Mean (SE) 
 
 
56.1 (0.3) 
 
57.6 (1.0) 
 
56.9 (0.8) 
 
55.6 (0.4) 
 
2, 841 
 
2.24 
 
0.11 
 
Comorbidities* (Survey) 
Mean (SE) 
 
 
1.5 (0.04) 
 
1.9 (0.1) 
 
 
1.4 (0.1) 
 
1.5 (0.04) 
 
2, 841 
 
3.73 
 
0.01 
 
Income (Survey) 
     High 
     Low 
 
 
 
 
513 (60.8%) 
331 (39.2%) 
 
 
 
44 (46.8%) 
50 (53.2%) 
 
 
 
83 (57.6%) 
61 (42.4%) 
 
 
 
386 (63.7%) 
220 (36.3%) 
 
 
 
2 
 
 
10.4 
 
 
0.005 
Education (Survey) 
     Less than high school 
     High School/GED 
     Some college 
     Bachelor Degree 
     Post grad education/other 
 
 
52 (6.2%) 
287 (34.0%) 
152 (18.0%) 
110 (13.0%) 
243 (28.8%) 
 
5 (5.3%) 
42 (44.7%) 
13 (13.8%) 
11 (11.7%) 
23 (24.5%) 
 
11 (7.6%) 
47 (32.6%) 
28 (19.4%) 
21 (14.6%) 
37 (25.7%) 
 
36 (5.9%) 
198 (32.7%) 
111 (18.3%) 
78 (12.9%) 
183 (30.2%) 
 
 
 
8 
 
 
 
7.22 
 
 
 
0.51 
Private Insurance (KCR) 
      Yes 
      No 
 
 
572 (67.8%) 
272 (32.2%) 
 
54 (57.5%) 
40 (42.6%) 
 
 
92 (63.9%) 
52 (36.1%) 
 
 
426 (70.3%) 
180 (29.7%) 
 
 
2 
 
7.34 
 
0.03 
Race (Survey) 
      Non-Hispanic White 
      Other 
 
 
796 (94.3%) 
48 (5.7%) 
 
90 (95.7%) 
4 (4.3%) 
 
137 (95.1%) 
7 (4.9%) 
 
569 (93.9%) 
37 (6.1%) 
 
2 
 
0.739 
 
0.69 
Stage at Diagnosis (KCR) 
      Stage 1/Stage 2 
      Stage 3/Stage 4 
       
 
611 (72.4%) 
233 (27.6%) 
 
71 (75.5%) 
23 (24.5%) 
 
107 (74.3%) 
37 (25.7%) 
 
433 (71.5%) 
1753(28.6%
) 
 
2 
 
0.99 
 
0.61 
Smoking Status (Survey) 
     Never Smoked 
     Former Smoker 
     Current Smoker 
 
504 (59.7%) 
249 (29.5%) 
91 (10.8%) 
 
45 (47.9%) 
34 (36.2%) 
15 (16.0%) 
 
 
83 (57.6%) 
46 (31.9%) 
15 (10.4%) 
 
376 (62.1%) 
169 (27.0%) 
61 (10.1%) 
 
 
4 
 
 
7.74 
 
 
0.10 
*average of comorbidities score from 0-6 
KCR=Data available from the Kentucky Cancer Registry 
Survey=Data available from telephone interviews with consenting women at least 12 months 
following diagnosis 
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Table 2. Unadjusted and adjusted linear regression comparing levels of partner support to 
number of days until first treatment. 
 
 Mean Days to First Treatment (SE) 
Unadjusted p-value Adjusted* p-value Adjusted** p-value 
Low Support 22.3 (1.8) 0.79 22.4 (1.9) 
 
0.75 22.2 (1.9) 0.66 
Moderate 
Support 
 
21.9 (1.5) 0.98 21.9 (1.5) 0.95 21.7  (1.5) 
 
0.82 
High support 
 
21.8 (0.7) ----- 21.7 (0.8) ----- 21.4 (0.8) ----- 
*adjusted for age at diagnosis and stage 
**adjusted for age at diagnosis, stage, comorbidities, and income  
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Figure 3. Kaplan-Meier estimate comparing levels of partner support to the number of 
days between diagnosis and treatment (low support=0, moderate support=1, high 
support=2), p=0.926. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23 
Table 3. Unadjusted and adjusted cox proportional hazards model comparing levels of 
partner support to number of days until first treatment. 
 
 Hazard Ratio (95% Confidence Interval) 
Unadjusted Adjusted* Adjusted** 
Low Support 0.96 (0.77, 1.19) 
 
0.95 (0.77, 1.19) 
 
0.95 (0.76, 1.18) 
Moderate Support 
 
0.99 (0.83, 1.19) 0.98 (0.82, 1.18) 0.97 (0.81, 1.16) 
High support (ref) 
 
----- ----- ----- 
*adjusted for age at diagnosis and stage 
**adjusted for age at diagnosis, stage, comorbidities, and income 
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Figure 4. Kaplan-Meier estimate comparing levels of partner support to the number of 
days between diagnosis and treatment for women diagnosed with early stage breast 
cancer (low support=0, moderate support=1, high support=2), p=0.415. 
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Table 4. Unadjusted and adjusted cox proportional hazards model comparing levels of 
partner support to number of days until first treatment for those diagnosed as stage 1 or 
stage 2 (early stage). 
 
Early Stage 
(N=611) 
Hazard Ratio (95% Confidence Interval) 
Unadjusted Adjusted* Adjusted** 
Low Support 0.93 (0.72, 1.20) 
 
0.92 (0.72, 1.19) 
 
0.91 (0.71, 1.18) 
Moderate Support 
 
1.12 (0.91, 1.38) 1.11 (0.90, 1.38) 1.09 (0.88, 1.35) 
High support (ref) 
 
----- ----- ----- 
*adjusted for age  
**adjusted for age at diagnosis, comorbidities, and income 
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Figure 5. Kaplan-Meier estimate comparing levels of partner support to the number of 
days between diagnosis and treatment for women diagnosed with late stage breast cancer 
(low support=0, moderate support=1, high support=2), p=0.196. 
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Table 5. Unadjusted and adjusted cox proportional hazards model comparing levels of 
partner support to number of days until first treatment for those diagnosed as stage 3 or 
stage 4 (late stage). 
 
Late Stage  
(N=233) 
Hazard Ratio (95% Confidence Interval) 
Unadjusted Adjusted* Adjusted** 
Low Support 1.10 (0.71, 1.70) 
 
1.11 (0.71, 1.72) 
 
1.15 (0.73, 1.82) 
Moderate Support 
 
0.74 (0.52, 1.07) 0.75 (0.52, 1.08) 0.74 (0.51, 1.06) 
High support (ref) 
 
----- ----- ----- 
*adjusted for age at diagnosis  
**adjusted for age at diagnosis, comorbidities, and income 
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Figure 6. Kaplan-Meier estimate comparing levels of partner support to the number of 
days between diagnosis and treatment for women receiving surgery as their first 
treatment (low support=0, moderate support=1, high support=2), p=0.833. 
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Table 6. Unadjusted and adjusted cox proportional hazards model comparing levels of 
partner support to number of days until first treatment for those receiving surgery as their 
first treatment. 
 
Surgery 
(N=785) 
Hazard Ratio (95% Confidence Interval) 
Unadjusted Adjusted* Adjusted** 
Low Support 0.94 (0.75, 1.18) 
 
0.93 (0.74, 1.17) 
 
0.91 (0.72, 1.14) 
Moderate Support 
 
1.01 (0.83, 1.21) 1.00 (0.83, 1.21) 0.98 (0.81, 1.19) 
High support (ref) 
 
----- ----- ----- 
*adjusted for age  
**adjusted for age at diagnosis, comorbidities, and income 
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Figure 7. Kaplan-Meier estimate comparing levels of partner support to the number of 
days between diagnosis and treatment for women receiving chemotherapy as their first 
treatment (low support=0, moderate support=1, high support=2), p=0.536. 
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Table 7. Unadjusted and adjusted cox proportional hazards model comparing levels of 
partner support to number of days until first treatment for those receiving chemotherapy 
as their first treatment. 
Chemotherapy 
(N=50) 
Hazard Ratio (95% Confidence Interval) 
Unadjusted Adjusted* Adjusted** 
Low Support 1.69 (0.51, 5.54) 
 
1.75 (0.53, 5.76) 
 
2.65 (0.74, 9.43) 
Moderate Support 
 
0.81 (0.37, 1.75) 0.98 (0.43, 2.21) 0.83 (0.35, 1.95) 
High support (ref) 
 
----- ----- ----- 
*adjusted for age  
**adjusted for age at diagnosis, comorbidities, and income 
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